<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00737191</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000588630</org_study_id>
    <secondary_id>P30CA015083</secondary_id>
    <secondary_id>MCS930</secondary_id>
    <secondary_id>07-007571</secondary_id>
    <nct_id>NCT00737191</nct_id>
  </id_info>
  <brief_title>Opioids With or Without Olanzapine in Treating Patients With Moderate to Severe Cancer Pain</brief_title>
  <official_title>Analgesic Effect of Olanzapine in Cancer Pain: A Double-Blind Randomized Placebo-Controlled Parallel Group Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Opioids lessen pain caused by cancer. It is not yet known whether opioids are more&#xD;
      effective when given together with or without olanzapine in treating cancer pain.&#xD;
&#xD;
      PURPOSE: This randomized clinical trial is studying opioids to see how well they work when&#xD;
      given together with or without olanzapine in treating patients with moderate to severe cancer&#xD;
      pain.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  To assess the analgesic effect of olanzapine when administered in combination with&#xD;
           opioids in patients with cancer pain.&#xD;
&#xD;
        -  To assess the opiod-sparing effect of olanzapine vs placebo.&#xD;
&#xD;
        -  To assess the effect of olanzapine on opioid adverse effects.&#xD;
&#xD;
      OUTLINE: Patients undergo opioid titration with a step 3 opioid to maintain a less than 4/10&#xD;
      level of pain (on a 0-10 numeric pain rating scale) to establish a opioid starting dose. When&#xD;
      the pain rating increases, patients are randomized to 1 of 3 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive oral opioid and oral placebo once daily for 4 weeks.&#xD;
&#xD;
        -  Arm II: Patients receive oral opioid and 2.5 mg oral olanzapine once daily for 4 weeks.&#xD;
&#xD;
        -  Arm III: Patients receive oral opioid and 5 mg oral olanzapine once daily for 4 weeks.&#xD;
&#xD;
      Patients undergo quality of life assessments at baseline and three times weekly by&#xD;
      questionnaires using a scale from 0-3 and pain assessments periodically by Brief Pain&#xD;
      Inventory, Edmonton Symptom Assessment Scale, Linear Analogue Scale Assessments, and&#xD;
      Mini-Mental State Examination.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No accrual; No patients enrolled&#xD;
  </why_stopped>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Two-point pain improvement from baseline (0-10 numeric pain rating scale)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of active treatment vs placebo</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of olanzapine on opiod adverse effects</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationships between endpoints</measure>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Hematopoietic/Lymphoid Cancer</condition>
  <condition>Pain</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive oral opioid and oral placebo once daily for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral opioid and 2.5 mg oral olanzapine once daily for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm III</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral opioid and 5 mg oral olanzapine once daily for 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>olanzapine</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_label>Arm III</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Moderate to severe cancer pain&#xD;
&#xD;
               -  Pain score ≥ 7/10 (0-10 numeric pain rating scale)&#xD;
&#xD;
               -  Requires strong opioids (step 3) for pain control or are already on stable doses&#xD;
                  of step 3 opioids&#xD;
&#xD;
          -  Opioid induced cognitive dysfunction or cognitive impairment, defined as cognitive&#xD;
             disorder not otherwise specified according to Diagnostic and Statistical Manual of&#xD;
             Mental Disorders (DSM-IV) allowed&#xD;
&#xD;
          -  No nonmalignant pain&#xD;
&#xD;
               -  If patient has both malignant and nonmalignant pain, eligibility will be&#xD;
                  determined by the predominant site of pain&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Life expectancy ≥ 3 months&#xD;
&#xD;
          -  Normal renal function&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Must have a telephone&#xD;
&#xD;
          -  Able to complete patient questionnaires alone or with assistance&#xD;
&#xD;
          -  No delirium&#xD;
&#xD;
          -  No hepatic dysfunction&#xD;
&#xD;
          -  No nursing home patients&#xD;
&#xD;
          -  No intractable nausea or vomiting&#xD;
&#xD;
          -  No true allergy or intolerance to opioids&#xD;
&#xD;
          -  No gastrointestinal pathology that influences absorption of opioids&#xD;
&#xD;
          -  No drug seeking behavior or recent substance abuse history&#xD;
&#xD;
          -  No major depression&#xD;
&#xD;
          -  No respiratory compromise&#xD;
&#xD;
          -  No evidence of severe or uncontrolled systemic disease (e.g., unstable or&#xD;
             uncompensated respiratory, cardiac, hepatic, or renal disease)&#xD;
&#xD;
          -  No evidence of any other significant clinical disorder or laboratory finding that&#xD;
             makes it undesirable for the patient to participate in the study&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  More than 1 month since prior radiotherapy, chemotherapy, or radionuclides&#xD;
&#xD;
          -  More than 1 month since prior bisphosphonates&#xD;
&#xD;
          -  No prior surgery that influences absorption of opioids&#xD;
&#xD;
          -  No concurrent therapeutic procedures or treatments that influence pain&#xD;
&#xD;
          -  No concurrent active radiation or antineoplastic therapies&#xD;
&#xD;
          -  No concurrent retroviral therapies&#xD;
&#xD;
          -  No concurrent drugs that interfere with CYP34A, CYP1A2, or CYP2D6&#xD;
&#xD;
          -  No concurrent drugs that interfere with morphine metabolism&#xD;
&#xD;
          -  No concurrent medications that will influence the disposition of morphine or methadone&#xD;
&#xD;
          -  No other concurrent antiemetics, antianxiety, or neuroleptic agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric E. Prommer, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>March 2012</verification_date>
  <study_first_submitted>August 15, 2008</study_first_submitted>
  <study_first_submitted_qc>August 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2008</study_first_posted>
  <last_update_submitted>March 7, 2012</last_update_submitted>
  <last_update_submitted_qc>March 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 9, 2012</last_update_posted>
  <responsible_party>
    <name_title>Eric E. Prommer, M.D.</name_title>
    <organization>Mayo Clinic Cancer Center</organization>
  </responsible_party>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <keyword>hematopoietic/lymphoid cancer</keyword>
  <keyword>pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cancer Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olanzapine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

